Metformin in Longevity Study (MILES)
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.
LongevityNext discovery hub
Trials
Trial designs, endpoints and evidence records interpreted in context.
Source-reviewed hub
9 source-reviewed records
Source-reviewed intelligence
Section intelligence
Directly related records lead this section.
Aging Trial Endpoints: A Role-Based Interpretation Framework Without False Equivalence
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
TAME: Trial Design, Endpoints, and Status Tracker
Evidence reviewed
Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.
Boundary: Design and status are not results; metformin is not established as an anti-aging treatment.
Source-reviewed intelligence
Related intelligence
Additional directly related records follow the section-specific lead set.
What DO-HEALTH Actually Tested: Omega-3, Biomarker Aging, and Endpoint Limits
Evidence reviewed
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Boundary: Clock changes are not proof of slower clinical aging, healthspan or lifespan.
From Preclinical Promise to Human Evidence: How to Read a Longevity Translation Claim
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
From 9 to 12 Hallmarks: What the Aging Framework Explains—and What It Does Not
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
BioAge Labs
Evidence reviewed
Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.
Boundary: Pipeline and source mapping, not clinical validation or investment analysis.
Immune Age Signals
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
GLP-1 Therapies and Longevity Claims: What Human Outcomes Support—and What Remains Untested
Evidence reviewed
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.
Boundary: Benefits in indicated high-risk populations do not establish direct slowing of aging or lifespan extension in generally healthy people.
LN Pro preview